Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

• Published in: Cell reports. Medicine Vol. 4; no. 10; p. 101212
• Main Authors: Tian, Meijie, Wei, Jun S., Shivaprasad, Nityashree, Highfill, Steven L., Gryder, Berkley E., Milewski, David, Brown, G. Tom, Moses, Larry, Song, Hannah, Wu, Jerry T., Azorsa, Peter, Kumar, Jeetendra, Schneider, Dina, Chou, Hsien-Chao, Song, Young K., Rahmy, Abdelrahman, Masih, Katherine E., Kim, Yong Yean, Belyea, Brian, Linardic, Corinne M., Dropulic, Boro, Sullivan, Peter M., Sorensen, Poul H., Dimitrov, Dimiter S., Maris, John M., Mackall, Crystal L., Orentas, Rimas J., Cheuk, Adam T., Khan, Javed
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 17.10.2023; Elsevier
• Subjects: Advanced Basic Science; Animals; CAR T cell therapy; Cell Line, Tumor; Child; FGFR4; Humans; Immunotherapy, Adoptive; Mice; Receptor, Fibroblast Growth Factor, Type 4 - genetics; Receptor, Fibroblast Growth Factor, Type 4 - metabolism; Receptors, Chimeric Antigen - genetics; rhabdomyosarcoma; Rhabdomyosarcoma - drug therapy; specific cytotoxicity; specific cytotoxicity; rhabdomyosarcoma; FGFR4; CAR T cell therapy

Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we descr...